Researchers have created a roadmap to improve national lung cancer screening rates that doubled lung cancer screening rates through their multidisciplinary lung cancer screening program, according to a study published in NEJM Catalyst.
In a Scandinavian trial (ALASCCA) reported in The New England Journal of Medicine, Martling et al found that low-dose aspirin reduced the risk of disease recurrence vs placebo in patients with PI3K-altered localized colorectal cancer.
Cornelia Ulrich, MS, PhD, has been elected by the members of the Association of American Cancer Institutes (AACI) to serve as Vice President/President-Elect of AACI’s Board of Directors. Dr. Ulrich is Chief Scientific Officer and Executive Director of the Comprehensive Cancer Center at Huntsman Cancer Institute at the University of Utah.
An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group has revealed that age-based classifications in the treatment of acute myeloid leukemia (AML) may be outdated and overly simplistic. Their findings were published by Cusan et al in the journal Leukemia.
The results of the multicenter Female Asian Nonsmoker Screening Study (FANSS) suggest that low-dose CT screening is feasible and has value for early lung cancer detection in the historically underserved demographic of Asian women with no history of smoking. These data from the largest United States–based lung cancer screening program dedicated to a nonsmoking population were presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.
Dan L. Longo, MD, MACP James O. Armitage, MD, FASCO In the 1940s, the first drugs proven to cause objective responses in human cancers were developed. Mechlorethamine was discovered as a possible treatment of lymphoid cancers after autopsies on military personnel exposed to mustard gas...
The European Society for Medical Oncology (ESMO) has released its first set of recommendations for the use of artificial intelligence (AI) large language models in oncology practice, called the ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP). The guidance was...
Although the process of obtaining insurance prior authorization before a patient’s medical procedure, service, or prescription has typically been left to clinicians, as cancer therapies grow increasingly complex, the burden of navigating prior authorization is increasingly being shared by patients...
The results of the multicenter Female Asian Nonsmoker Screening Study (FANSS) suggest that low-dose CT screening is feasible and has value for early lung cancer detection in the historically underserved demographic of Asian women with no history of smoking. These data from the largest United...
Enzalutamide in combination with leuprolide demonstrated a significantly longer overall survival than either leuprolide or enzalutamide monotherapy in patients with biochemically recurrent prostate cancer, according to the final overall survival analysis of the phase III EMBARK trial presented at...
In the phase III HARMONi trial, when ivonescimab was given with carboplatin plus pemetrexed, vs the chemotherapy regimen alone, after a third-generation tyrosine kinase inhibitor, patients with EGFR-mutated non–small cell lung cancer (NSCLC) had a significant delay in disease progression.1...
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non–small cell lung cancer (NSCLC), according to data from the phase I/II SOHO-01 clinical trial. Over 70% of the patients studied saw their tumors shrink or disappear. The results ...